+26%

est. 2Y upside i

Series A

Nanotechnology-enabled coatings for automotive and defence sectors

Rank

#2683

Sector

Advanced Materials

Est. Liquidity

~2Y

Data Quality

Data: Low

Alchemy is a credible but high-risk equity opportunity best suited to a candidate who values near-term liquidity over maximum upside.

Last updated: May 5, 2026

Bull (35%)+70%

Alchemy's IPO (announced March 27, 2026) gains strong traction with defense-sector investors as Canadian Armed Forces contracts scale and NATO/Five Eyes partnerships are announced, driving the market cap toward ~$60-70M within 2 years. The 143% YoY growth rate holds as ExoShield achieves broader OEM distribution and Crypsis Class earns its first international defense contract, validating the dual-vertical strategy and re-rating the stock well above the estimated ~$25M Series A post-money valuation.

Base (50%)+15%

Alchemy lists as a micro-cap on a Canadian exchange with limited institutional coverage and thin float, yielding modest post-IPO appreciation of ~15% over 2 years as the company converts growth into early revenue milestones. Defense procurement timelines delay meaningful Crypsis Class revenue while ExoShield's 400+ installer network grows steadily but cannot move the valuation needle materially at this stage.

Bear (15%)-40%

Post-IPO dilution from follow-on offerings needed to fund operations — no disclosed revenue and only $6.42M in total lifetime funding — combined with micro-cap illiquidity, drives a 40% drawdown from the offer price. Larger advanced-materials incumbents or defense primes crowd out Alchemy's pipeline and the 143% growth rate proves unsustainable off a negligible revenue base.

Est. time to liquidity~1.5 years

Preference Stack Risk

moderate

Funding Intensity

26%

Total funding of $6.42M against an estimated Series A post-money valuation of ~$25M implies a ~25.7% liquidation preference overhang (high range); however, the announced IPO would convert preferred shares to common equity, effectively eliminating the preference stack for employee shareholders if and when the offering closes.

Dilution Risk

high

With no disclosed revenue and only $6.42M raised over 12 years of operation, Alchemy will almost certainly require additional capital via secondary IPO offerings or follow-on raises within the 2-year horizon, creating meaningful dilution risk for all employee equity holders.

Secondary Liquidity

limited

Post-IPO listing provides in-principle liquidity, but micro-cap Canadian exchange listings (CSE/TSX-V) typically carry thin average daily volume making block sales of employee shares difficult without material price impact; a standard 180-day post-IPO lock-up also applies.

Other — 21 roles

View all 21 open roles at Alchemy →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Alchemy's data — designed to show you've done your homework.

  • 1

    “What is Alchemy's current ARR or revenue run-rate — specifically what percentage comes from ExoShield product sales versus Crypsis Class defense contracts — and what is the realized gross margin on each segment?”

  • 2

    “What is the IPO share structure: total diluted share count, expected offering price range, employee lock-up duration, and will current option grants convert at IPO or require re-grant at the public offering price?”

  • 3

    “How many active defense contracts exist beyond the Canadian Armed Forces, what is the typical contract size and duration, and are there any pending NATO or Five Eyes procurement opportunities already in the pipeline?”

Community

Valuation Sentiment

Our model estimates +26% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.